

Sophia Zoungas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8460358/publications.pdf>

Version: 2024-02-01

143
papers

12,081
citations

71102

41
h-index

27406

106
g-index

146
all docs

146
docs citations

146
times ranked

14590
citing authors

#	ARTICLE	IF	CITATIONS
1	A co-designed integrated kidney and diabetes model of care improves mortality, glycaemic control and self-care. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1472-1481.	0.7	1
2	Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysis. <i>European Heart Journal</i> , 2022, 43, 3243-3254.	2.2	22
3	Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 467-476.	1.9	5
4	Exploring HbA1c variation between Australian diabetes centres: The impact of centre-level and patient-level factors. <i>PLoS ONE</i> , 2022, 17, e0263511.	2.5	2
5	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. <i>Nature Medicine</i> , 2022, 28, 591-598.	30.7	139
6	Making the most of audit and feedback to improve diabetes care: a qualitative study of the perspectives of Australian Diabetes Centres. <i>BMC Health Services Research</i> , 2022, 22, 255.	2.2	1
7	Cardiovascular disease and malignant melanoma. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, .	1.2	3
8	Effects of a Lifestyle Intervention to Prevent Deterioration in Glycemic Status Among South Asian Women With Recent Gestational Diabetes. <i>JAMA Network Open</i> , 2022, 5, e220773.	5.9	19
9	Mental Health Outcomes in Australian Healthcare and Aged-Care Workers during the Second Year of the COVID-19 Pandemic. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4951.	2.6	12
10	Management of type 2 diabetes in young adults aged 18â€“30 years: ADS/ADEA/APEG consensus statement. <i>Medical Journal of Australia</i> , 2022, 216, 422-429.	1.7	7
11	The Cost of Control: Cost-effectiveness Analysis of Hybrid Closed-Loop Therapy in Youth. <i>Diabetes Care</i> , 2022, 45, 1971-1980.	8.6	8
12	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 975-982.	1.8	35
13	<scp>Sodiumâ€“glucose coâ€“transporterâ€“2</scp> inhibitors with and without metformin: A metaâ€“analysis of cardiovascular, kidney and mortality outcomes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 382-390.	4.4	40
14	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2021, 174, 385-394.	3.9	110
15	Glycaemia and utilisation of technology across the lifespan of adults with type 1 diabetes: Results of the Australian National Diabetes Audit (ANDA). <i>Diabetes Research and Clinical Practice</i> , 2021, 171, 108609.	2.8	9
16	Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. <i>Diabetologia</i> , 2021, 64, 275-287.	6.3	140
17	The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2021, 99, 34-47.	5.2	195
18	Novel Lipid Species for Detecting and Predicting Atrial Fibrillation in Patients With Type 2 Diabetes. <i>Diabetes</i> , 2021, 70, 255-261.	0.6	9

#	ARTICLE	IF	CITATIONS
19	SGLT2 Inhibitors in Diabetic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 631-633.	4.5	22
20	The authors reply. <i>Kidney International</i> , 2021, 99, 1241.	5.2	0
21	HIGH-SENSITIVITY CARDIAC TROPONIN T FOR THE DETECTION OF MYOCARDIAL INJURY AND RISK STRATIFICATION IN COVID-19. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3145.	2.8	4
22	Impact of COVID-19 on Diabetes Health Care and Service Provision in Australian Diabetes Centers. <i>Diabetes Care</i> , 2021, 44, e163-e164.	8.6	5
23	Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control. <i>Diabetologia</i> , 2021, 64, 2012-2025.	6.3	24
24	Protective lipid-lowering variants in healthy older individuals without coronary heart disease. <i>Open Heart</i> , 2021, 8, e001710.	2.3	1
25	Trends in glycaemic control and drug use in males and females with type 2 diabetes: Results of the <scp>Australian National Diabetes Audit</scp> from 2013 to 2019. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2603-2613.	4.4	6
26	Statins: Neurobiological underpinnings and mechanisms in mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 693-708.	6.1	15
27	Older participant perspectives on permanent study drug discontinuation in an ongoing primary prevention trial of statins. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 841-847.	1.9	3
28	The Efficacy of Technology in Type 1 Diabetes: A Systematic Review, Network Meta-analysis, and Narrative Synthesis. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 411-421.	4.4	49
29	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. <i>Kidney International</i> , 2020, 98, S1-S115.	5.2	692
30	The association of smoking status with glycemic control, metabolic profile and diabetic complicationsâ€” Results of the Australian National Diabetes Audit (ANDA). <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107626.	2.3	21
31	Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis. <i>Diabetes Care</i> , 2020, 43, 1967-1975.	8.6	30
32	Are SGLT2 Inhibitors Safe and Effective in Advanced Diabetic Kidney Disease?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1694-1695.	4.5	1
33	Type 2 Diabetes Patients' Perspectives, Experiences, and Barriers Toward Diabetes-Related Self-Care: A Qualitative Study From Pakistan. <i>Frontiers in Endocrinology</i> , 2020, 11, 534873.	3.5	21
34	Prevalence, incidence and risk factors of diabetes in Australian adults aged 45 years: A cohort study using linked routinely-collected data. <i>Journal of Clinical and Translational Endocrinology</i> , 2020, 22, 100240.	1.4	6
35	Cost-effectiveness of health technologies in adults with type 1 diabetes: a systematic review and narrative synthesis. <i>Systematic Reviews</i> , 2020, 9, 171.	5.3	20
36	Therapy Escalation Following an Elevated HbA1c in Adults Aged 45 Years and Older Living With Diabetes in Australia: A Real-World Observational Analysis. <i>Diabetes Care</i> , 2020, 43, e185-e187.	8.6	1

#	ARTICLE	IF	CITATIONS
37	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. <i>The Cochrane Library</i> , 2020, 2020, CD009966.	2.8	9
38	Cost-Effectiveness Analysis of a Hybrid Closed-Loop System Versus Multiple Daily Injections and Capillary Glucose Testing for Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 812-821.	4.4	19
39	Development, Relative Validity and Reproducibility of the Aus-SDS (Australian Short Dietary Screener) in Adults Aged 70 Years and above. <i>Nutrients</i> , 2020, 12, 1436.	4.1	11
40	Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?. <i>Atherosclerosis</i> , 2020, 304, 1-8.	0.8	36
41	Health-related quality of life among patients with comorbid diabetes and kidney disease attending a codesigned integrated model of care: a longitudinal study. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000842.	2.8	11
42	Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A1c in the ADVANCE Trial. <i>Diabetes Care</i> , 2020, 43, 1293-1299.	8.6	15
43	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. <i>Kidney International</i> , 2020, 98, 839-848.	5.2	193
44	Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness. <i>Pharmacoeconomics</i> , 2020, 38, 1095-1113.	3.3	28
45	Young-onset type 2 diabetes and younger current age: increased susceptibility to retinopathy in contrast to other complications. <i>Diabetic Medicine</i> , 2020, 37, 991-999.	2.3	33
46	Trends in the Dispensing and Costs of Glucose-Lowering Medications Among Older Australians: Findings from National Claims Data. <i>Drugs and Aging</i> , 2020, 37, 393-398.	2.7	5
47	ADVANCE in context: The benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 5-11.	4.4	12
48	EXamining ouTcomEs in chroNic Disease in the 45 and Up Study (the EXTEND45 Study): Protocol for an Australian Linked Cohort Study. <i>JMIR Research Protocols</i> , 2020, 9, e15646.	1.0	9
49	Recent Patterns of Multimorbidity Among Older Adults in High-Income Countries. <i>Population Health Management</i> , 2019, 22, 127-137.	1.7	120
50	The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study. <i>PLoS ONE</i> , 2019, 14, e0219685.	2.5	11
51	Outcomes of people with severe hypoglycaemia requiring prehospital emergency medical services management: a prospective study. <i>Diabetologia</i> , 2019, 62, 1868-1879.	6.3	7
52	Prevalence and impact of non-cardiovascular comorbidities among older adults hospitalized for non-ST segment elevation acute coronary syndrome. <i>Cardiovascular Diagnosis and Therapy</i> , 2019, 9, 250-261.	1.7	17
53	Association between Dietary Intake and Lipid-Lowering Therapy: Prospective Analysis of Data from Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Using a Quantile Regression Approach. <i>Nutrients</i> , 2019, 11, 1858.	4.1	7
54	Reply to: Statins for Primary Prevention in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 857-858.	2.6	0

#	ARTICLE	IF	CITATIONS
55	Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 862-872.	4.5	29
56	Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes. <i>Scientific Reports</i> , 2019, 9, 3256.	3.3	14
57	A need-based approach to self-management education for adults with co-morbid diabetes and chronic kidney disease. <i>BMC Nephrology</i> , 2019, 20, 113.	1.8	8
58	Association between Heat Exposure and Hospitalization for Diabetes in Brazil during 2000â€“2015: A Nationwide Case-Crossover Study. <i>Environmental Health Perspectives</i> , 2019, 127, 117005.	6.0	45
59	Predictors of first-year nonadherence and discontinuation of statins among older adults: a retrospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 227-235.	2.4	32
60	Potential mechanisms underlying the cardiovascular benefits of sodium glucose cotransporter 2 inhibitors: a systematic review of data from preclinical studies. <i>Cardiovascular Research</i> , 2019, 115, 266-276.	3.8	38
61	Predictors of statin use among older adults: A nationwide cross-sectional study. <i>Journal of Clinical Lipidology</i> , 2019, 13, 156-162.e1.	1.5	7
62	A lifestyle intervention programme for the prevention of Type 2 diabetes mellitus among South Asian women with gestational diabetes mellitus [LIVING study]: protocol for a randomized trial. <i>Diabetic Medicine</i> , 2019, 36, 243-251.	2.3	11
63	Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 63-68.	2.3	9
64	Do sulphonylureas still have a place in clinical practice?. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 821-832.	11.4	83
65	Patterns of statin use and long-term adherence and persistence among older adults with diabetes. <i>Journal of Diabetes</i> , 2018, 10, 699-707.	1.8	32
66	Models of care for co-morbid diabetes and chronic kidney disease. <i>Nephrology</i> , 2018, 23, 711-717.	1.6	14
67	A Systematic Review and Meta-analysis of the Factors Associated With Nonadherence and Discontinuation of Statins Among People Aged ≥ 65 Years. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 798-805.	3.6	46
68	Adherence and Persistence Among Statin Users Aged 65 Years and Over: A Systematic Review and Meta-analysis. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2018, 73, 813-819.	3.6	63
69	Age, age at diagnosis and diabetes duration are all associated with vascular complications in type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2018, 32, 279-290.	2.3	56
70	Measures of Population Ageing in Australia from 1950 to 2050. <i>Journal of Population Ageing</i> , 2018, 11, 367-385.	1.4	16
71	Patterns of Medication Dispensation for Multiple Comorbidities among Older Adults in Australia. <i>Pharmacy (Basel, Switzerland)</i> , 2018, 6, 134.	1.6	3
72	Patient reported barriers are associated with low physical and mental well-being in patients with co-morbid diabetes and chronic kidney disease. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 215.	2.4	5

#	ARTICLE	IF	CITATIONS
73	Effect of Comorbidity Assessed by the Charlson Comorbidity Index on the Length of Stay, Costs and Mortality among Older Adults Hospitalised for Acute Stroke. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 2532.	2.6	48
74	Statins for Primary Prevention in Older Adults—Moving Toward Evidence-Based Decision-Making. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 2188-2196.	2.6	50
75	A1C Targets Should Be Personalized to Maximize Benefits While Limiting Risks. <i>Diabetes Care</i> , 2018, 41, 1121-1124.	8.6	43
76	A 10-Year Trend in Statin Use Among Older Adults in Australia: an Analysis Using National Pharmacy Claims Data. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 265-272.	2.6	24
77	Depression and diabetes distress in adults with type 2 diabetes: results from the Australian National Diabetes Audit (ANDA) 2016. <i>Scientific Reports</i> , 2018, 8, 7846.	3.3	80
78	Impact of informed consent content and length on recruitment of older adults into a community based primary prevention trial. <i>Contemporary Clinical Trials Communications</i> , 2018, 11, 89-94.	1.1	10
79	Comparing two methods for delivering clinical trial informed consent information to older adults: singular versus stepped approach. <i>Clinical Trials</i> , 2018, 15, 610-615.	1.6	2
80	Burden of cardiovascular risk factors and disease among patients with type 1 diabetes: results of the Australian National Diabetes Audit (ANDA). <i>Cardiovascular Diabetology</i> , 2018, 17, 77.	6.8	25
81	Risk-adjustment of diabetes health outcomes improves the accuracy of performance benchmarking. <i>Scientific Reports</i> , 2018, 8, 10261.	3.3	7
82	Effectiveness of self-management support interventions for people with comorbid diabetes and chronic kidney disease: a systematic review and meta-analysis. <i>Systematic Reviews</i> , 2018, 7, 84.	5.3	51
83	Prevalence and Incidence of Statin Use and 3-Year Adherence and Discontinuation Rates Among Older Adults With Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 527-534.	1.9	11
84	LDL-Cholesterol Is the Only Clinically Relevant Biomarker for Atherosclerotic Cardiovascular Disease (ASCVD) Risk. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 235-238.	4.7	10
85	Evaluating optimal utilisation of technology in type 1 diabetes mellitus from a clinical and health economic perspective: protocol for a systematic review. <i>Systematic Reviews</i> , 2018, 7, 44.	5.3	6
86	Geographical variation of diabetic emergencies attended by prehospital Emergency Medical Services is associated with measures of ethnicity and socioeconomic status. <i>Scientific Reports</i> , 2018, 8, 5122.	3.3	3
87	Younger people with Type 2 diabetes have poorer self-care practices compared with older people: results from the Australian National Diabetes Audit. <i>Diabetic Medicine</i> , 2018, 35, 1087-1095.	2.3	27
88	Age-related differences in glycaemic control, cardiovascular disease risk factors and treatment in patients with type 2 diabetes: a cross-sectional study from the Australian National Diabetes Audit. <i>BMJ Open</i> , 2018, 8, e020677.	1.9	21
89	Predicting 6-month mortality risk of patients commencing dialysis treatment for end-stage kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw383.	0.7	20
90	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. <i>The Cochrane Library</i> , 2017, 2, CD009966.	2.8	20

#	ARTICLE	IF	CITATIONS
91	The genomic potential of the Aspirin in Reducing Events in the Elderly and Statins in Reducing Events in the Elderly studies. <i>Internal Medicine Journal</i> , 2017, 47, 461-463.	0.8	14
92	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 431-437.	11.4	379
93	Factors associated with patient activation in an Australian population with comorbid diabetes and chronic kidney disease: a cross-sectional study. <i>BMJ Open</i> , 2017, 7, e017695.	1.9	38
94	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. <i>Diabetes Care</i> , 2017, 40, 1273-1284.	8.6	462
95	Microvascular outcomes in type 2 diabetes – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 580.	11.4	0
96	The association between patient activation and self-care practices: A cross-sectional study of an Australian population with comorbid diabetes and chronic kidney disease. <i>Health Expectations</i> , 2017, 20, 1375-1384.	2.6	51
97	Time series modelling to forecast prehospital EMS demand for diabetic emergencies. <i>BMC Health Services Research</i> , 2017, 17, 332.	2.2	23
98	Self-management in patients with diabetes and chronic kidney disease is associated with incremental benefit in HRQOL. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 427-432.	2.3	24
99	Individual, social and environmental factors and their association with weight in rural-dwelling women. <i>Australian and New Zealand Journal of Public Health</i> , 2017, 41, 158-164.	1.8	10
100	Intensive glucose control in patients with diabetes prevents onset and progression of microalbuminuria, but effects on end-stage kidney disease are still uncertain. <i>Evidence-Based Medicine</i> , 2017, 22, 219-220.	0.6	1
101	Utilisation of prehospital emergency medical services for hyperglycaemia: A community-based observational study. <i>PLoS ONE</i> , 2017, 12, e0182413.	2.5	6
102	Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review. <i>JMIR Research Protocols</i> , 2017, 6, e39.	1.0	4
103	Primary and tertiary health professionals' views on the health-care of patients with co-morbid diabetes and chronic kidney disease – a qualitative study. <i>BMC Nephrology</i> , 2016, 17, 50.	1.8	17
104	Utilisation of emergency medical services for severe hypoglycaemia: An unrecognised health care burden. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 1081-1086.	2.3	25
105	Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1796-1803.	8.6	79
106	Plasma Lipidomic Profiles Improve on Traditional Risk Factors for the Prediction of Cardiovascular Events in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2016, 134, 1637-1650.	1.6	205
107	Obesity, polycystic ovary syndrome and breastfeeding: an observational study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 458-466.	2.8	30
108	Identifying health service barriers in the management of co-morbid diabetes and chronic kidney disease in primary care: a mixed-methods exploration. <i>Family Practice</i> , 2016, 33, 492-497.	1.9	19

#	ARTICLE	IF	CITATIONS
109	How much is enough? An investigation of the relationship between haemodialysis adequacy and quality of life of elderly patients. <i>Nephrology</i> , 2016, 21, 314-320.	1.6	3
110	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. <i>Diabetes Care</i> , 2016, 39, 694-700.	8.6	184
111	The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax) Tj ETQq1 1097843140 BT / Ome	10.97843140	140
112	The Perspectives of Patients on Health-Care for Co-Morbid Diabetes and Chronic Kidney Disease: A Qualitative Study. <i>PLoS ONE</i> , 2016, 11, e0146615.	2.5	40
113	Predictors of Health-Related Quality of Life in Patients with Co-Morbid Diabetes and Chronic Kidney Disease. <i>PLoS ONE</i> , 2016, 11, e0168491.	2.5	33
114	Diabetic kidney disease. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15018.	30.5	542
115	Effectiveness of management models for facilitating self-management and patient outcomes in adults with diabetes and chronic kidney disease. <i>Systematic Reviews</i> , 2015, 4, 81.	5.3	9
116	Hypertension in Reproductive-Aged Women With Polycystic Ovary Syndrome and Association With Obesity. <i>American Journal of Hypertension</i> , 2015, 28, 847-851.	2.0	76
117	Relationship Between Levels of Advanced Glycation End Products and Their Soluble Receptor and Adverse Outcomes in Adults With Type 2 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1891-1897.	8.6	62
118	Predicting the Effects of Blood Pressure Lowering Treatment on Major Cardiovascular Events for Individual Patients With Type 2 Diabetes Mellitus. <i>Hypertension</i> , 2015, 65, 115-121.	2.7	24
119	A new blood glucose management algorithm for type 2 diabetes: a position statement of the Australian Diabetes Society. <i>Medical Journal of Australia</i> , 2014, 201, 650-653.	1.7	46
120	Intensification of medication and glycaemic control among patients with type 2 diabetes—the ADVANCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 426-432.	4.4	14
121	Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes. <i>Diabetologia</i> , 2014, 57, 2465-2474.	6.3	346
122	Statins in the elderly. <i>Current Opinion in Cardiology</i> , 2014, 29, 372-380.	1.8	14
123	Impact of Visit-to-Visit Glycemic Variability on the Risks of Macrovascular and Microvascular Events and All-Cause Mortality in Type 2 Diabetes: The ADVANCE Trial. <i>Diabetes Care</i> , 2014, 37, 2359-2365.	8.6	284
124	Follow-up of Blood-Pressure Lowering and Glucose Control in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2014, 371, 1392-1406.	27.0	520
125	Defining the relationship between average glucose and HbA1c in patients with type 2 diabetes and chronic kidney disease. <i>Diabetes Research and Clinical Practice</i> , 2014, 104, 84-91.	2.8	24
126	Aortic Pulse Wave Velocity Improves Cardiovascular Event Prediction. <i>Journal of the American College of Cardiology</i> , 2014, 63, 636-646.	2.8	1,446

#	ARTICLE	IF	CITATIONS
127	Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. <i>Kidney International</i> , 2013, 83, 517-523.	5.2	256
128	Weight changes and their predictors amongst 11 140 patients with type 2 diabetes in the ADVANCE trial. <i>Diabetes, Obesity and Metabolism</i> , 2012, 14, 464-469.	4.4	38
129	Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. <i>Diabetologia</i> , 2012, 55, 636-643.	6.3	262
130	Does Glycemic Control Offer Similar Benefits Among Patients With Diabetes in Different Regions of the World?. <i>Diabetes Care</i> , 2011, 34, 2491-2495.	8.6	32
131	Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 393-398.	2.8	127
132	The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. <i>Diabetologia</i> , 2010, 53, 821-831.	6.3	112
133	Severe Hypoglycemia and Risks of Vascular Events and Death. <i>New England Journal of Medicine</i> , 2010, 363, 1410-1418.	27.0	1,279
134	The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. <i>Diabetes Research and Clinical Practice</i> , 2010, 89, 126-133.	2.8	39
135	Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 2068-2074.	8.6	230
136	Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1813-1821.	6.1	787
137	ARTERIAL STIFFNESS AND CARDIOVASCULAR OUTCOME. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2007, 34, 647-651.	1.9	100
138	Association of Carotid Intima-Medial Thickness and Indices of Arterial Stiffness With Cardiovascular Disease Outcomes in CKD. <i>American Journal of Kidney Diseases</i> , 2007, 50, 622-630.	1.9	108
139	Cardiovascular Morbidity and Mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in Chronic Renal Failure. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1108-1116.	2.8	208
140	Atherosclerosis and folic acid supplementation trial in chronic renal failure: Baseline results. <i>Nephrology</i> , 2004, 9, 130-141.	1.6	37
141	Arterial function after successful renal transplantation. <i>Kidney International</i> , 2004, 65, 1882-1889.	5.2	95
142	A placebo-controlled trial of long-term oral combined continuous hormone replacement therapy in postmenopausal women: effects on arterial compliance and endothelial function. <i>Clinical Endocrinology</i> , 2001, 55, 673-682.	2.4	46
143	Carotid Artery Intima-Medial Thickness Is Increased In Chronic Renal Failure. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2000, 27, 639-641.	1.9	39